About OPSL

Organ Preservation Solutions Ltd.

OPSL is a dynamic early stage company set up to develop and bring to the market next generation products in the field of organ transplantation. We are developing a pipeline of solutions that ensure we move to the forefront of transplantation solutions globally. Our aim is to disrupt the worldwide transplant solution market with the first proven technological advance in decades.

OPSL was founded to innovate products in the field of organ preservation and transplantation to improve patient and clinical outcomes. The initial, near market technologies are based on decades of research carried out in the NHS by one of Europe’s leading transplant surgeons, Professor Peter Lodge – Clinical Director of Surgery at Leeds Teaching Hospitals, and Dr David Potts – Honorary Visiting Lecturer in Pharmacology at Leeds University.

 

OPSL was incorporated in January 2016 with investment from Brightstar Partners, who bring unique expertise in commercialising cutting-edge medical technology.  

 

OPSL works with a close network of leading professional bodies and contract organisations that deliver the pre-clinical, clinical, regulatory and manufacturing services necessary to develop our products for market.

The People Behind OPSL

OPSL has a strong management team and board bringing together specialist sector knowledge and commercial acumen.

Prof J Peter A Lodge

Prof J Peter A Lodge

Co-founder

Professor Peter Lodge – co-inventor of the technology – is regarded as one of Europe’s top transplant surgeons. He holds the positions of Consultant in Hepatopancreatobiliary and Transplant Surgery (St James's University Hospital) and Professor of Surgery (University of Leeds) and has been Clinical Director for Surgery for Leeds Teaching Hospitals NHS Trust. Prof Lodge has been a consultant surgeon since 1992.


He trained in surgery in Yorkshire and at Harvard Medical School, where he worked during 1991-2. His main interests have been in hepato-pancreato-biliary and transplantation surgery, for which he has been awarded many national and international honours. As one of the UK’s most experienced surgeons, he has carried out more than 2000 liver resections, 950 liver transplants, 850 kidney transplants and he is also experienced in pancreas, intestinal and multivisceral grafts.
He recently initiated live donor liver transplantation in Leeds, providing improved services for NHS patients. Prof Lodge has published more than 200 papers in peer reviewed journals and has written 28 book chapters, including “Liver” in the most recent edition of Gray’s Anatomy.​

Dr David Potts

Dr David Potts

Co-founder

Dr David Potts – co-inventor of the technology – graduated with a London University Degree in Pharmacy and Membership of the Pharmaceutical Society. His main interests were in Pharmacology, Pharmaceutical Chemistry, Pharmacy and Physiology. He joined Leeds University in 1964 to read for a PhD in water and salt balance within the Department of Physiology.

He was awarded a US Government Travelling Fellowship to work at the National Institutes of Health, Bethesda, Maryland from 1971-1972 where he learned the techniques of isolated perfusion of kidney tubules, a state of the art approach to the study of kidney tubule epithelial cells.

It was the subsequent application of this technique in Leeds that led to his interest in organ preservation and his realisation that transplant preservation solutions could be improved by developing their effectiveness in studies of the function of isolated tissues and organs.

Mal Jarmolowicz

Mal Jarmolowicz

CEO

Mal is an experienced life science start-up CEO and is responsible for OPSL’s direction and strategy. She has experience across both large Pharma – including Degussa Pharmaceuticals & Glaxo Wellcome (now GlaxoSmithKline) – and medical technology start-ups where she has held Board level positions since 2000.

Mal was CEO of Celltran Ltd for six years, launching two ATMPs and acquiring Belgium based Xcellentis. She has raised significant finance for early stage companies, and has gained regulatory approvals in med-tech and in the emerging field of regenerative medicine.

Mal holds an MBA, and studied Pharmaceutical Science. She is a member of the OPSL Board of Directors.

Dr Clare Lankester

Dr Clare Lankester

Senior Development Manager

Clare has extensive experience working across the industrial, academic, and clinical interface to develop and exploit opportunities for the commercialisation of multi-disciplinary research.

After completing a PhD in Biochemistry, Clare worked for a university spin out company for six years where she was responsible for leading the scientific and technical development of innovative healthcare technologies.

Seun Olarewaju

Seun Olarewaju

Quality Manager

Seun is responsible for setting up and running the OPSL’s quality system and the day-to-day operations of the organisation, bringing 10 years’ experience in quality management and operational excellence within academic, biotechnology and medical device companies.

With experience at Genzyme Biosurgery (Cambridge, USA), UK Stem Cell Bank and Smith & Nephew (York, UK), she has in-depth knowledge and understanding of international and statutory regulations, managing workstreams within GMP and GLP environments. She is GLP-trained and a certified ISO9001 auditor.

Seun is PMI PMP (project management professional) and APMG PRINCE2 Certified.

 

Richard Clark

Richard Clark

Director, Medipex | OPSL Director

In 2002 Richard setup and ran Medipex as CEO for 13 years until 2017 where he now serves as a Director. He helped make Medipex one of the UK’s most successful healthcare innovation hubs, which now has an international reputation. He successfully led the creation of an innovation pathway within the NHS, with over 80 commercial deals including taking 8 new start-up businesses through incubation and investment.

 

Richard is a Chartered Engineer with 35 years’ experience in project management, consulting and technology transfer; within environmental, power generation and medical engineering industries.

 

Richard is a member of the OPSL Board of Directors.

Tony Rabar

Tony Rabar

Managing Partner, Brightstar Partners | OPSL Director

Tony has 20 years’ experience as a serial technology entrepreneur across high-tech manufacturing, healthcare and services ventures. He is currently the managing partner of venture development firm Brightstar Partners, who specialise in commercialising cutting-edge medical technologies. 

Tony has advised executives and senior management in major corporations on corporate venturing, disruptive technologies and new business start-ups. At Origin Energy, Australia’s largest energy company, he oversaw a portfolio of early stage and profitable internal ‘start-ups’.

In 2003, he was appointed as sole in-house entrepreneur by the board of directors to Qinetiq Plc. In the late 90’s he established an early stage technology and start-up incubator focused on medical and healthcare technologies, working within major UK academic technology centres. 

Tony is a member of the OPSL Board of Directors.

Minsoo Kang

Minsoo Kang

Kiwoon Investment | OPSL Director

A professional venture capitalist with 12 years of experience in bio-industry R&D and venture capital. Prior to working as a venture capitalist, Minsoo worked in Bio-venture (Bio-van) and a Food manufacturing company (Haitai) R&D department.

In 2008, he joined a venture capital firm (AJU IB Investment) and has been involved with investments in 15+ venture companies. He joined Kiwoom Investment in 2012 as an investment professional and holds the role of fund manager in 2 venture funds.

His investment portfolio focuses on bio & healthcare sectors based on his experience. He has successful exit experience (I-Sense, KangStem Biotech, Korea Bone Bank, etc) in IPO, M&A and trade sales.